# Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

> **NCT02954172** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 450 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Bevacizumab in Combination With Paclitaxel/Carboplatin
- **DRUG:** IBI305 in Combination with Paclitaxel/Carboplatin

## Key facts

- **NCT ID:** NCT02954172
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-28
- **Primary completion:** 2018-10-19
- **Final completion:** 2019-11-12
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954172, "Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02954172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*